Stifel Downgrades Health Catalyst to Hold, Lowers Price Target to $16
Stifel analyst David Grossman downgrades Health Catalyst (NASDAQ:HCAT) from Buy to Hold and lowers the price target from $27 to $16.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Health Catalyst’s Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Health Catalyst's (NASDAQ:HCAT) reported sales totaled $68.09 million. Despite a 54.16% increase in earnings, the company posted a loss of $22.46 million.
Citigroup Maintains Buy on Health Catalyst, Lowers Price Target to $25
Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from $45 to $25.
SVB Leerink Maintains Outperform on Health Catalyst, Lowers Price Target to $22
SVB Leerink analyst Stephanie Davis maintains Health Catalyst (NASDAQ:HCAT) with a Outperform and lowers the price target from $48 to $22.
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Where Health Catalyst Stands With Analysts
Over the past 3 months, 8 analysts have published their opinion on Health Catalyst (NASDAQ:HCAT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.